The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Boston Scientific; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Nippon Kayaku; Taiho Pharmaceutical
Speakers' Bureau - Kyowa Hakko Kirin
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Shire
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Taiho Pharmaceutical (Inst)
 
Gakuto Ogawa
No Relationships to Disclose
 
Akira Fukutomi
Honoraria - Lilly Japan; Sawai Pharmaceutical Co; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - ASLAN Pharmaceuticals (Inst); NanoCarrier (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); Yakult Honsha (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca Japan; Bayer Yakuhin; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shire; Taiho Pharmaceutical; Takara Bio; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tosiya Sato
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Tomohiro Kadota
No Relationships to Disclose
 
Tatsuya Ioka
Honoraria - Daiichi Sankyo; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Otsuka; Shire; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Mochida Pharmaceutical Co. Ltd.; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Taiho Pharmaceutical; Taiho Pharmaceutical (Inst)
 
Kazuya Sugimori
No Relationships to Disclose
 
Naohiro Sata
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai
 
Kyoko Shimizu
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pharma Valley Center (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Taiho Pharmaceutical
 
Hiroshi Ishii
Honoraria - Eisai; Taiho Pharmaceutical; TOWA; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)